Product
Peginterferon Lambda-1a
1 clinical trial
1 indication
Indication
Hepatitis DClinical trial
Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients With Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2)Status: Active (not recruiting), Estimated PCD: 2024-06-15